Lantern Pharma (LTRN) Other financing activities (2020 - 2026)

Lantern Pharma (LTRN) has reported Other financing activities for 5 consecutive years, with $887.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Other financing activities changed N/A year-over-year to $887.0; the trailing twelve-month figure through Jun 2026 stood at $12881.0 (changed N/A YoY), and the FY2025 full-year result was $13442.0, down 79.85% from the prior year.
• Other financing activities slipped to $887.0 in Q2 2026 per LTRN's latest filing, from $11994.0 in the prior quarter.
• Across five years, Other financing activities topped out at $299788.0 in Q1 2022 and bottomed at $887.0 in Q2 2026.
• Historically, Other financing activities has averaged $91846.2 across 3 years, with a median of $33355.0 in 2024.
• The widest YoY moves for Other financing activities: up 312.06% in 2022, down 312.06% in 2022.
• Over 3 years, Other financing activities stood at $299788.0 in 2022, then slumped by 96.0% to $11994.0 in 2024, then plunged by 92.6% to $887.0 in 2026.
• According to Business Quant data, Other financing activities over the past three periods registered $887.0, $11994.0, and $54716.0 for Q2 2026, Q3 2024, and Q1 2024 respectively.